Predicting Survival in Patients Undergoing Resection for Locally Recurrent Retroperitoneal Sarcoma: A Study and Novel Nomogram from TARPSWG
Chandrajit P. Raut(Dana-Farber Cancer Institute), Alessandro Gronchi(Fondazione IRCCS Istituto Nazionale dei Tumori), Carol J. Swallow(University Health Network), Marco Fiore(Fondazione IRCCS Istituto Nazionale dei Tumori), Vittorio Quagliuolo(Humanitas University), Venu G. Pillarisetty(University of Washington), Kenneth Cardona(Emory University), Hans Gelderblom(Leiden University Medical Center), Jean‐Yves Blay(Université Claude Bernard Lyon 1), Rosalba Miceli(Fondazione IRCCS Istituto Nazionale dei Tumori), Frits van Coevorden(The Netherlands Cancer Institute), Antonino De Paoli(Centro di Riferimento Oncologico), Giovanni Grignani(Candiolo Cancer Institute), Francesco Barretta(Fondazione IRCCS Istituto Nazionale dei Tumori), Carolyn Nessim(University of Ottawa), D. Strauß(Royal Marsden Hospital), Robert J. Canter(Virginia Tech), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Mark Fairweather(Brigham and Women's Hospital), Sanjay P. Bagaria(WinnMed), Eberhard Stoeckle(Institut Bergonié), John T. Mullen(Massachusetts General Hospital), Ricardo González(Moffitt Cancer Center), Elisabetta Pennacchioli(European Institute of Oncology), Guy Lahat(Tel Aviv University), Nita Ahuja(Johns Hopkins University), Dario Callegaro(Fondazione IRCCS Istituto Nazionale dei Tumori)
Cited by 116
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k